Is Sekisui Chemical profitable in 2026?

Yes. Sekisui Chemical reported net income of ¥75.17 billion for the fiscal year ended March 31, 2026, on consolidated net sales of ¥1,309.3 billion, though operating profit fell ¥1.5 billion year over year to ¥106.5 billion, missing January 2026 guidance.

Is Sekisui Chemical laying off workers?

Headcount is slightly declining rather than a mass layoff. As of March 31, 2026 Sekisui Chemical had 26,752 consolidated employees, down 166 (-0.62%) year over year, alongside a narrowing from 145 to 142 consolidated subsidiaries by December 2025.

Could AI replace Sekisui Chemical's diagnostics business?

Partially at the margins. Sekisui Diagnostics' own blog (January 23, 2026) acknowledges AI taking a more active role managing lab workflows, and rival Roche partnered with PathAI on AI pathology in February 2024, while Sekisui has no reported frontier AI diagnostic product of its own.

Who is Sekisui Chemical's biggest competitor?

In diagnostics, Roche, Abbott, and Danaher dwarf Sekisui's Medical segment; in interlayer films, Kuraray is the direct rival, currently on the losing end of patent litigation, with German and Korean courts upholding Sekisui's PVB film patents against Kuraray through July 2026.

Who owns Sekisui Chemical?

Sekisui Chemical is publicly traded on the Tokyo Stock Exchange (ticker 4204) with no controlling parent. As of March 31, 2026 its largest disclosed shareholders were The Dai-ichi Life Insurance Company at 3.00% and Sekisui House, Ltd. at 1.97%.

What is Sekisui Chemical's new growth plan?

On May 21, 2026 Sekisui Chemical launched 'Accelerate 2028,' a three-year medium-term plan covering FY2026-2028 with ¥700 billion in planned investment, split between ¥300 billion for M&A and ¥400 billion in capex including a 1GW perovskite solar cell production line.

Biotech tools companies · Japan

Sekisui Chemical Co., Ltd.

sekisuichemical.com ↗

Japanese maker of interlayer films, housing materials, pipes, and medical diagnostics.

Hard to displace

Assessed 26 July 2026 · Evidence as of 26 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 26 July 2026 · Checkable from Q3 FY2026 (December 2026) · Every call on the record Checkpoint: FY2026 full-year results reporting against ¥1,408.4B sales and ¥115.0B operating profit guidance

The call

The core materials businesses keep the group steady while the diagnostics division shrinks under pressure from bigger, better-funded rivals.

Sekisui Chemical makes plastic films for car windshields, housing materials, and water pipes, plus medical diagnostic tests. The plastic and pipe businesses are hard to replace because they own patent protections and long customer relationships, but the diagnostics unit is much smaller and losing money fast against bigger rivals like Roche and Abbott; Sekisui is already selling off diagnostics brands and writing down the division. The key question is whether Sekisui can pull off an ambitious plan to build a new factory making next-generation solar panels by 2028 without burning through cash so fast that it weakens the whole company.

Why

AI pressure: Roche/PathAI AI-assisted pathology tools. Roche already paired with PathAI on AI pathology while Sekisui's diagnostics unit shrinks and takes impairments. Could AI do the core job? Unlikely.

Bigger players: Roche, Abbott, Danaher in diagnostics. These giants run diagnostics at a scale Sekisui Medical can't match, and Sekisui is pruning that division, not growing it. Could a giant copy it? Probably.

What protects it. Interlayer film, housing, and pipe businesses generate most of the ¥1.3T revenue and sit behind patents and regulatory approvals Roche-type rivals don't touch.

What would change this call

Sekisui Medical announces another divestiture or impairment beyond Virotech/XenoTech by FY2027. Would show continued retreat from diagnostics against larger rivals.
Munich or Seoul courts rule on Kuraray's appeal of the interlayer film patent injunction. A loss would open Sekisui's core film moat to competition.
FY2026 results (due ~April 2027) checked against ¥1,408.4B sales / ¥115.0B operating profit guidance. A second consecutive miss would confirm operating pressure beyond diagnostics.

Key numbers

FY2025 net sales: ¥1,309.3 billion (2026-03-31)
Operating profit ¥106.5B, missed guidance (2026-03-31)
Medical segment impairment: ¥14.9 billion (2026-03-31)

Named risks

Medical/diagnostics segment took ¥14.9bn impairment and divested Virotech GmbH in FY2025. Severity: medium
Perovskite solar scale-up (¥220bn for 1GW line) carries capex overrun risk within Accelerate 2028 plan. Severity: medium
FY2025 operating profit missed January 2026 guidance despite record sales. Severity: low
Ongoing Kuraray patent appeals could reopen interlayer film competition if reversed. Severity: low
New CEO (since March 2026) faces first full medium-term plan execution test. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Kuraray	gaining on	German and Korean courts upheld Sekisui's PVB film patents against Kuraray through July 2026
Roche	losing to	Roche's Feb 2024 PathAI partnership outpaces Sekisui's diagnostics AI efforts, per Jan 2026 company blog
Abbott	losing to	Named as a larger IVD/point-of-care leader while Sekisui remains a smaller regional diagnostics player
Danaher	losing to	Larger scale in diagnostics as Sekisui prunes its unit via 2025 impairments and divestitures

Questions people ask

Is Sekisui Chemical profitable in 2026?: Yes. Sekisui Chemical reported net income of ¥75.17 billion for the fiscal year ended March 31, 2026, on consolidated net sales of ¥1,309.3 billion, though operating profit fell ¥1.5 billion year over year to ¥106.5 billion, missing January 2026 guidance.
Is Sekisui Chemical laying off workers?: Headcount is slightly declining rather than a mass layoff. As of March 31, 2026 Sekisui Chemical had 26,752 consolidated employees, down 166 (-0.62%) year over year, alongside a narrowing from 145 to 142 consolidated subsidiaries by December 2025.
Could AI replace Sekisui Chemical's diagnostics business?: Partially at the margins. Sekisui Diagnostics' own blog (January 23, 2026) acknowledges AI taking a more active role managing lab workflows, and rival Roche partnered with PathAI on AI pathology in February 2024, while Sekisui has no reported frontier AI diagnostic product of its own.
Who is Sekisui Chemical's biggest competitor?: In diagnostics, Roche, Abbott, and Danaher dwarf Sekisui's Medical segment; in interlayer films, Kuraray is the direct rival, currently on the losing end of patent litigation, with German and Korean courts upholding Sekisui's PVB film patents against Kuraray through July 2026.
Who owns Sekisui Chemical?: Sekisui Chemical is publicly traded on the Tokyo Stock Exchange (ticker 4204) with no controlling parent. As of March 31, 2026 its largest disclosed shareholders were The Dai-ichi Life Insurance Company at 3.00% and Sekisui House, Ltd. at 1.97%.
What is Sekisui Chemical's new growth plan?: On May 21, 2026 Sekisui Chemical launched 'Accelerate 2028,' a three-year medium-term plan covering FY2026-2028 with ¥700 billion in planned investment, split between ¥300 billion for M&A and ¥400 billion in capex including a 1GW perovskite solar cell production line.

Timeline

2026-07-15German and Korean courts uphold Sekisui's PVB interlayer film patents against Kuraray
2026-05-21Sekisui launches 'Accelerate 2028' medium-term plan with ¥700bn investment, incl. perovskite solar
2026-04-28FY2025 results: record ¥1,309.3bn sales but operating profit misses guidance at ¥106.5bn
2026-03-01Ikusuke Shimizu becomes President and CEO, Keita Kato moves to Chairman
2026-02-16Sekisui announces representative director change ahead of March 2026 CEO transition
2026-01-23Sekisui Diagnostics blog names AI-managed lab workflows a 2026 clinical diagnostics trend
2025-10-16Sekisui, Fujitsu and SAP Japan announce SAP S/4HANA Cloud rollout to ~100 group companies
2025-05-01Sekisui Medical and Sekisui Chemical sell Sekisui Virotech GmbH to Virotech Diagnostics Holdings

Revision history

26 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE